DiscGenics completed enrollment in its Phase I/II first-in-human U.S. clinical study of injectable disc cell therapy (IDCT), an allogeneic treatment for degenerative disc disease (DDD).
The two-year prospective, randomized, double-blinded, vehicle- and placebo-controlled, multicenter clinical study will examine IDCT in patients with symptomatic, single-level, mild to moderate lumbar DDD. All 60 subjects have been treated with no reported safety issues.
Eligible subjects were randomized to one of four treatment cohorts: low dose IDCT (n=20), high dose IDCT (n=20), vehicle (n=10) and placebo (n=10). Each subject received a single intradiscal injection of his or her assigned treatment into the target symptomatic lumbar intervertebral disc. Primary outcome measures include safety and reduction in pain; secondary outcome measures include reduction in disability and radiographic improvement.
IDCT is also being evaluated in a multicenter safety study in Japan.
DiscGenics completed enrollment in its Phase I/II first-in-human U.S. clinical study of injectable disc cell therapy (IDCT), an allogeneic treatment for degenerative disc disease (DDD).
DiscGenics completed enrollment in its Phase I/II first-in-human U.S. clinical study of injectable disc cell therapy (IDCT), an allogeneic treatment for degenerative disc disease (DDD).
The two-year prospective, randomized, double-blinded, vehicle- and placebo-controlled, multicenter clinical study will examine IDCT in patients with symptomatic, single-level, mild to moderate lumbar DDD. All 60 subjects have been treated with no reported safety issues.
Eligible subjects were randomized to one of four treatment cohorts: low dose IDCT (n=20), high dose IDCT (n=20), vehicle (n=10) and placebo (n=10). Each subject received a single intradiscal injection of his or her assigned treatment into the target symptomatic lumbar intervertebral disc. Primary outcome measures include safety and reduction in pain; secondary outcome measures include reduction in disability and radiographic improvement.
IDCT is also being evaluated in a multicenter safety study in Japan.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
